drugset

drugset / Trial / NCT07192939

Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis

NCT07192939 ↗

Phase 2 Recruiting 270 enrolled Guangdong Hengrui Pharmaceutical Co., Ltd

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy and safety of HRS-9813 in subjects with pulmonary fibrosis。

Timeline

Start: 2025-10-29
Primary completion: 2028-06
Completion: 2028-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HRS-9813	Unknown	—	—

Indications